Celsius Therapeutics Inc.

https://www.celsiustx.com

Celsius Therapeutics is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key players in disease and by identifying the genes that are triggering their malfunction. The company is applying a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover first-in-class precision therapies that have a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018 and is backed by Third Rock Ventures and GV (formerly Google Ventures) and is based in Cambridge, Mass. *

	Start	2018-05-15 established (approx)
	Predecessor	Broad Institute (MIT / Harvard)
	Industry	BIOTECH
	Industry 2	biomarker discovery services
	Person	Kassum, Tariq (Celsius Therapeutics 201906– CEO before Obsidian Therapeutics + Millennium Pharmaceuticals/Takeda)
	Person 2	Lengauer, Christoph (Third Rock Ventures 201807 Venture Partner + Germany (govt) 201601 CEO of GALS)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	399 Binney Street
	City	02139 Cambridge, MA
	Tel	+1-857-776-7400
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Celsius Therapeutics Inc.. (5/15/18). "Press Release: Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics For People with Autoimmune Diseases and Cancer". Cambridge, MA.

		Record changed: 2023-07-10